×
About 45,674 results

ALLMedicine™ Immunosuppression Center

Research & Reviews  22,311 results

Sequential paternal haploidentical donor liver and HSCT in EPP allow discontinuation of...
https://doi.org/10.1111/petr.14040
Pediatric Transplantation; Malkiel S, Sayed BA et. al.

Jun 2nd, 2021 - EPP is characterized by photosensitivity and by liver disease. When LT is performed in EPP, recurrence often occurs in the allograft due to ongoing protoporphyrin production in bone marrow. Therefore, curative treatment requires allogeneic HSCT af...

SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection.
https://doi.org/10.1172/JCI141965
The Journal of Clinical Investigation; Tsai TY, Huang MT et. al.

Jun 1st, 2021 - Chronic hepatitis B (CHB) infection is rarely eradicated by current antiviral nucleos(t)ide analogues. We found that α2,6-biantennary sialoglycans of HBV surface antigen (HBsAg) bound human SIGLEC-3 (CD33) by IP and ELISA, and the binding affinity...

Ferroptosis suppressive genes correlate with immunosuppression in glioblastoma.
https://doi.org/10.1016/j.wneu.2021.05.098
World Neurosurgery; Deng S, Zhenga Y et. al.

Jun 1st, 2021 - Glioblastoma (GBM) is the most lethal primary tumor in the central nervous system. Ferroptosis is an iron-dependent cell death. This study aims to identify prognostic ferroptosis-related genes and their role in tumor immunity. We identified by dif...

COVID-19 in advanced Duchenne/Becker muscular dystrophy patients.
https://doi.org/10.1016/j.nmd.2021.03.011
Neuromuscular Disorders : NMD; Levine H, Prais D et. al.

May 31st, 2021 - Duchenne muscular dystrophy (DMD) is the most common childhood muscular dystrophy. As a result of progressive muscle weakness, pulmonary function decreases during the second decade of life and lung disease contributes significantly to morbidity an...

Basil Polysaccharide Reverses Development of Experimental Model of Sepsis-Induced Secon...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149242
Mediators of Inflammation; Chen X, He Y et. al.

May 31st, 2021 - Basil polysaccharide (BPS) represents a main active ingredient extracted from basil (Ocimum basilicum L.), which can regulate secondary bacterial pneumonia development in the process of sepsis-mediated immunosuppression. In this study, a dual mode...

see more →

Guidelines  31 results

Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in pat...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116237
Annals of Hematology; Classen AY, Henze L et. al.

Apr 13th, 2021 - Hematologic and oncologic patients with chemo- or immunotherapy-related immunosuppression are at substantial risk for bacterial infections and Pneumocystis jirovecii pneumonia (PcP). As bacterial resistances are increasing worldwide and new resear...

Monitoring of Donor-specific Anti-HLA Antibodies and Management of Immunosuppression in...
https://doi.org/10.1097/TP.0000000000003270 10.1097/TP.0000000000001129 10.1097/TP.0000000000001040 10.1111/trf.12064 10.1111/ajt.14752 10.1016/0197-2456(95)00134-4 10.1097/TP.0000000000001651 10.1111/j.1600-6143.2004.00360.x 10.1111/j.1600-6143.2012.04013.x 10.1155/2017/5201098 10.1097/TP.0b013e31827a19cc 10.1111/ajt.12589 10.1111/ajt.12590 10.1097/TP.0000000000000869 10.1038/nrneph.2012.81 10.1097/TP.0b013e3181a44206 10.1097/TP.0b013e3182139da1 10.1111/j.1600-6143.2012.04251.x 10.1097/TP.0b013e3182543950 10.1038/ki.2012.190 10.1097/TP.0b013e31827d62e3 10.1111/j.1600-6143.2012.04325.x 10.1111/ajt.12859 10.1097/01.TP.0000438196.30790.66 10.1097/TP.0000000000000216 10.1111/j.1600-6143.2008.02441.x 10.1016/j.humimm.2007.01.006 10.1681/ASN.2016030368 10.1056/NEJMoa1302506 10.1681/ASN.2009101065 10.1111/j.1600-6143.2006.01721.x 10.1097/TP.0b013e3182777f28 10.1038/ki.2015.275 10.1097/TP.0000000000001487 10.1681/ASN.2014040326 10.1111/j.1399-3046.2011.01599.x 10.1097/TP.0b013e318203fd26 10.1097/TP.0b013e3181ac6198 10.1111/j.1432-2277.2008.00755.x 10.1111/j.1600-6143.2009.02800.x 10.1111/ajt.13010 10.1016/j.trre.2016.02.002 10.1681/ASN.2012070664 10.1111/ajt.13295 10.1016/j.humimm.2016.05.025 10.1681/ASN.2014080837 10.1097/TP.0b013e31822872dd 10.1097/01.TP.0000441091.47464.c6 10.1681/ASN.2014111120 10.1016/j.healun.2010.08.020 10.1111/ajt.13700 10.1007/s00467-016-3322-8 10.1097/TP.0b013e3182888db6 10.1681/ASN.2013101144 10.1097/TP.0000000000000315 10.1111/ajt.12287 10.1111/ajt.12462 10.1016/j.inmuno.2013.10.003 10.1097/01.TP.0000441362.11232.48 10.1111/tri.12648 10.1016/j.trim.2013.07.002 10.1371/journal.pmed.1002572 10.1111/j.1600-6143.2011.03961.x 10.5301/jn.5000207 10.1093/ndt/gfu208 10.1111/ajt.12365 10.1681/ASN.2014040399 10.1111/j.1600-6143.2009.02764.x 10.1111/j.1600-6143.2011.03840.x 10.1111/ajt.13132 10.1111/ajt.13795 10.1111/ajt.13803 10.1093/ndt/gfq096 10.1111/tri.12798 10.1038/ki.2013.465 10.1038/ki.2013.484 10.1111/j.1600-6143.2006.01360.x 10.1136/bmj.38569.471007.AE 10.1016/j.trre.2015.01.002 10.3109/03602532.2016.1151037 10.1186/2047-1440-3-7 10.1097/TP.0b013e3182292426 10.1152/jappl.1989.66.3.1397 10.1097/TXD.0000000000000536 10.1136/bmj.h3163 10.1097/TP.0000000000000384 10.1097/FTD.0b013e3182708edf 10.1016/j.clinthera.2014.02.021 10.1111/ajt.14504 10.1097/TP.0b013e318199c1c7 10.1111/ajt.14109 10.1097/TXD.0000000000000710 10.1681/ASN.2017030287 10.1111/j.1600-6143.2009.02726.x 10.1097/01.tp.0000110408.83054.88 10.1111/j.1600-6143.2008.02495.x 10.1097/MD.0000000000002196 10.7182/prtr.21.4.f044g7v3r803838t 10.1097/TP.0b013e3182725532 10.1371/journal.pone.0165233 10.1016/j.transproceed.2015.11.027 10.1016/j.transproceed.2014.07.011 10.1093/ndt/gfr374 10.1016/j.trim.2008.08.005 10.1097/TP.0000000000000958 10.1111/ajt.12493 10.1002/14651858.CD004759.pub2 10.1097/TP.0000000000000064 10.1111/j.1600-6143.2009.02968.x 10.1097/TP.0000000000000592 10.1111/ajt.13871 10.1111/ajt.13663 10.1111/ajt.14228 10.1097/TP.0b013e31825d1587 10.1097/TP.0000000000002049 10.1111/j.1600-6143.2006.01613.x 10.1097/00007890-198305000-00006 10.1097/00007890-198108000-00019 10.1111/j.1600-6143.2009.02591.x 10.1016/j.transproceed.2015.01.030 10.1111/j.1399-0012.2008.00902.x 10.1111/ajt.14520 10.1681/ASN.2017070818 10.1111/ajt.14001
Transplantation Crespo M, Zárraga S et. al.

Jul 13th, 2020 - Monitoring of Donor-specific Anti-HLA Antibodies and Management of Immunosuppression in Kidney Transplant Recipients: An Evidence-based Expert Paper.|2020|Crespo M,Zárraga S,Alonso Á,Beneyto I,Díaz Corte C,|blood,diagnosis,immunology,prevention & ...

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: P...
https://doi.org/10.1016/j.ejca.2020.01.007
European Journal of Cancer (Oxford, England : 1990); Stratigos AJ, Garbe C et. al.

Mar 2nd, 2020 - Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in the white populations, accounting for 20% of all cutaneous malignancies. Factors implicated in cSCC etiopathogenesis include ultraviolet radiation exposure and ...

FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
http://hugin.info/152918/R/2233733/878824.pdf

Feb 5th, 2019 - The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the firs...

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASC...
https://doi.org/10.1200/JCO.18.00374
Journal of Clinical Oncology : Official Journal of the Am... Taplitz RA, Kennedy EB et. al.

Sep 4th, 2018 - To provide an updated joint ASCO/Infectious Diseases Society of America (IDSA) guideline on antimicrobial prophylaxis for adult patients with immunosuppression associated with cancer and its treatment. ASCO and IDSA convened an update Expert Panel...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  22,735 results

Sequential paternal haploidentical donor liver and HSCT in EPP allow discontinuation of...
https://doi.org/10.1111/petr.14040
Pediatric Transplantation; Malkiel S, Sayed BA et. al.

Jun 2nd, 2021 - EPP is characterized by photosensitivity and by liver disease. When LT is performed in EPP, recurrence often occurs in the allograft due to ongoing protoporphyrin production in bone marrow. Therefore, curative treatment requires allogeneic HSCT af...

SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection.
https://doi.org/10.1172/JCI141965
The Journal of Clinical Investigation; Tsai TY, Huang MT et. al.

Jun 1st, 2021 - Chronic hepatitis B (CHB) infection is rarely eradicated by current antiviral nucleos(t)ide analogues. We found that α2,6-biantennary sialoglycans of HBV surface antigen (HBsAg) bound human SIGLEC-3 (CD33) by IP and ELISA, and the binding affinity...

Ferroptosis suppressive genes correlate with immunosuppression in glioblastoma.
https://doi.org/10.1016/j.wneu.2021.05.098
World Neurosurgery; Deng S, Zhenga Y et. al.

Jun 1st, 2021 - Glioblastoma (GBM) is the most lethal primary tumor in the central nervous system. Ferroptosis is an iron-dependent cell death. This study aims to identify prognostic ferroptosis-related genes and their role in tumor immunity. We identified by dif...

COVID-19 in advanced Duchenne/Becker muscular dystrophy patients.
https://doi.org/10.1016/j.nmd.2021.03.011
Neuromuscular Disorders : NMD; Levine H, Prais D et. al.

May 31st, 2021 - Duchenne muscular dystrophy (DMD) is the most common childhood muscular dystrophy. As a result of progressive muscle weakness, pulmonary function decreases during the second decade of life and lung disease contributes significantly to morbidity an...

Basil Polysaccharide Reverses Development of Experimental Model of Sepsis-Induced Secon...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149242
Mediators of Inflammation; Chen X, He Y et. al.

May 31st, 2021 - Basil polysaccharide (BPS) represents a main active ingredient extracted from basil (Ocimum basilicum L.), which can regulate secondary bacterial pneumonia development in the process of sepsis-mediated immunosuppression. In this study, a dual mode...

see more →

News  595 results

Managing Diffuse Peripheral Ischemia in Antiphospholipid Syndrome: Anticoagulation, Immunosuppression, or Vasodilation?
https://www.medscape.com/viewarticle/948988

Apr 13th, 2021 - This article originally appeared on Hospital for Special Surgery's website. Case Report A 39-year-old man with a history of well-controlled type 1 diabetes (T1D) since childhood and migraine presented with 1 week of pain and cyanosis of the finger...

IBD Centers Urged to Become Vaccination Hubs
https://www.medscape.com/viewarticle/948137

Mar 28th, 2021 - NEW YORK (Reuters Health) - Implementing vaccine services in inflammatory bowel disease (IBD) centers is "critical" to improving immunization rates, researchers say. "Vaccinating patients with IBD has been recognized to be impactful in preventing ...

Stem Cell Transplant Shows Long-term Benefit in MS
https://www.medscape.com/viewarticle/944656

Jan 24th, 2021 - The benefits of autologous hematopoietic stem cell transplant (AHSCT) for patients with multiple sclerosis (MS) persist for more than 10 years in the majority of patents, new data show. The study reports on 210 Italian patients who underwent AHSCT...

Dexamethasone May Curb Efficacy of Immune Checkpoint Blockade in Glioblastoma
https://www.medscape.com/viewarticle/941951

Dec 3rd, 2020 - NEW YORK (Reuters Health) - Dexamethasone given to combat cerebral edema in patients with glioblastoma may negatively affect immunotherapy, according to work in mice and clinical data. "There are many biologic, endogenous factors contributing to i...

NICE Recommends Innovative Treatment for Severe Blood Disorder for NHS Use
https://www.medscape.com/viewarticle/941022

Nov 15th, 2020 - A brand-new treatment – one of the first for 25 years – for acute acquired thrombotic thrombocytopenic purpura (aTTP) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine use in the NHS. Caplacizumab (Ca...

see more →